Sucampo to be Added to the NASDAQ Biotechnology Index Business Wire BETHESDA, Md. -- May 15, 2013 Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) (SPI) today announced that NASDAQ OMX Group, Inc. (NASDAQ: NDAQ) will include the company in the NASDAQ Biotechnology Index^® (NASDAQ: NBI) effective prior to market open on Monday, May 20, 2013. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is a modified market capitalization weighted index. Among the various criteria that must be met in order to be eligible for inclusion in this index are a market capitalization of at least $200 million and an average daily trading volume of at least 100,000 shares. The NASDAQ Biotechnology Index is re-ranked semi-annually in May and November. About Sucampo Pharmaceuticals, Inc. Sucampo Pharmaceuticals, Inc. is a global pharmaceutical company focused on innovative research, discovery, development and commercialization of proprietary drugs based on prostones. The therapeutic potential of prostones was first discovered by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo’s Chairman, Chief Executive Officer, Chief Scientific Officer, and co-founder. Prostones, naturally occurring fatty acid metabolites that have emerged as promising compounds with unique physiological activities, can be targeted for the treatment of unmet or underserved medical needs. For more information, please visit www.sucampo.com. AMITIZA is a registered trademark of Sucampo AG. The Sucampo logo and the tagline, The Science of Innovation, are registered trademarks of Sucampo AG. Contact: Sucampo Pharmaceuticals, Inc. Silvia Taylor, 1-240-223-3718 firstname.lastname@example.org
Sucampo to be Added to the NASDAQ Biotechnology Index
Press spacebar to pause and continue. Press esc to stop.